[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600883":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":30,"responsibleParty":41,"collaborators":25,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":25,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":25,"enrollmentInfo":53,"targetDuration":25,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":25,"overallStatus":62,"whyStopped":25,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A","EXPERIMENTAL","Period 1 : Reference Drug(AD-1161), Period 2 : Test Drug(AD-116)",[13,14],"Drug: AD-116","Drug: AD-1161",{"label":16,"type":10,"description":17,"interventionNames":18},"Sequence B","Period 1 : Test Drug(AD-116), Period 2 : Reference Drug(AD-1161)",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","AD-116","AD-116 Oral Tablet",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"AD-1161","AD-1161 Oral Capsule",[9,16],[31],{"facility":32,"status":25,"city":33,"state":25,"zip":25,"country":34,"countryCode":25,"cosmosGeoPoint":35,"geoPoint":40,"contacts":25},"H Plus Yangji Hospital","Seoul","South Korea",{"type":36,"coordinates":37},"Point",[38,39],126.9784,37.566,{"lat":39,"lon":38},{"type":42,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100600883","phase-1-a-clinical-trial-to-evaluate-the-safety-and-the-pharmacokinetics-of-ad-116-compared-to-ad-1161-in-healthy-adult-male-volunteers-100600883",false,"NCT07103278","A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers Under Fasting Conditions","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy adult male volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"MALE","19 Years",{"count":54,"type":55},44,"ACTUAL","INTERVENTIONAL",[58],"PHASE1","The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-116 and the administration of AD-1161 in healthy adult male volunteers",[61],"Benign Prostatic Hyperplasia","COMPLETED","2026-07-26",{"date":65,"type":55},"2026-07-28",{"date":67,"type":55},"2026-01-22",{"date":69,"type":55},"2026-03-07",{"name":5,"class":6},1]